Zentalis Pharmaceuticals, Inc. (ZNTL)

11.71 +0.60 (+5.40%) 收市：04:00PM EDT

Zentalis Pharmaceuticals, Inc.

1359 Broadway
Suite 1710
New York, NY 10018
United States
212 433 3791
https://zentalis.com

版塊: Healthcare
行業: Biotechnology
全職員工: 124

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Kimberly Lynn Blackwell M.D.	CEO & Director	1.17M	無	1969
Mr. Cameron S. Gallagher M.B.A.	Co-Founder, President, Interim CFO, Interim Treasurer & Director	892.15k	無	1970
Ms. Andrea Paul J.D.	Chief Legal Officer & Corporate Secretary	682.47k	無	1981
Dr. Diana F. Hausman M.D.	Chief Medical Officer & Director	38.44k	無	1963
Mr. Vincent Vultaggio	VP of Finance & Interim Principal Accounting Officer	無	無	1983
Dr. Mark Lackner Ph.D.	Chief Scientific Officer	無	無	1968
Ms. Kimberly Freeman	Chief Strategy Officer	無	無	無
Dr. Kyle Rasbach Ph.D., Pharm.D.	Chief Business Officer	無	無	1980
Dr. Adrian Jubb M.D., Ph.D.	Executive Vice President of Clinical Development	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

公司管治

截至 2024年5月1日 止，Zentalis Pharmaceuticals, Inc. 的 ISS 管治質素評分為 10。 Pillar 分數正在審核中：7；董事會：5；股東權利：8；現金賠償：10。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。